Overview

Open Label, Adaptive, Parallel Group PET Study Using RO7017773 And [11C] RO15-4513

Status:
Completed
Trial end date:
2018-06-22
Target enrollment:
Participant gender:
Summary
This is a single dose (SD), non-randomized, open-label, adaptive, parallel group study with the purpose of investigating the occupancy of alpha5-containing GABAA receptors by RO7017773 in healthy participants.
Phase:
Phase 1
Details
Lead Sponsor:
Hoffmann-La Roche